Eli Lilly developed the diabetes drug Mounjaro and is headquartered in Indianapolis, Indiana. Mounjaro is the brand name for tirzepatide, a prescription medicine approved in the United States for improving blood-sugar control in adults with type 2 diabetes.
Colonel Eli Lilly founded the company in Indianapolis in 1876. It grew from a pharmaceutical manufacturer into a multinational research-based company with medicines in diabetes, oncology, immunology, neuroscience, and other fields.
Mounjaro is distinct from Zepbound, another Eli Lilly brand using tirzepatide for chronic weight management in eligible adults. The company’s market capitalization has been heavily affected by expectations for demand, clinical results, regulatory decisions, and competition in metabolic medicines.